This post was originally published on this site
Johnson & Johnson’s COVID-19 vaccine showed promising signs in a small laboratory study of protecting against the Delta variant spreading across the U.S. and other countries, the company said.
In laboratory testing, the vaccine triggered strong levels of neutralizing antibodies in blood samples taken from eight vaccinated people, J&J
JNJ,
said Thursday.
